Abzena PLC Block Listing Update (9961J)

TIDMABZA

RNS Number : 9961J

Abzena PLC

03 July 2017

Abzena plc

Block Listing Update

Cambridge, UK, 3 July 2017 - Further to the announcement by Abzena plc (AIM: ABZA, 'Abzena' or the 'Group') on 9 January 2017, since 9 January 2017 and 3 July 2017, the Group announces that a total of nil ordinary shares of GBP0.002 each in the share capital of the Group ('Ordinary Shares') have been issued since that date pursuant to the Group's 2013 Share Incentive Plan and admitted to trading in accordance with the block listing applied for on 7 July 2015 (the 'Block Listing'). An update in accordance with Schedule 6 of the AIM Rules for Companies is set out below. The Group holds no shares in treasury and hence the total number of current voting rights is 213,603,903.

BLOCK LISTING SIX MONTHLY RETURN

 
 Name of applicant:                                    Abzena plc 
----------------------------------------------------  ---------------------------------------------------------------- 
 Name of scheme:                                       Abzena plc 2013 Share Incentive Plan 
----------------------------------------------------  ---------------------------------------------------------------- 
 Period of return:           From:                     9 January 2017             To:        3 July 2017 
--------------------------  ------------------------  -------------------------  ---------  -------------------------- 
 Balance of unallotted securities under scheme(s) 
  from previous return:                                757,476 
----------------------------------------------------  ---------------------------------------------------------------- 
 Plus: The amount by which the block scheme(s) has     nil 
 been increased since the date of the last 
 return (if any increase has been applied for): 
----------------------------------------------------  ---------------------------------------------------------------- 
 Less: Number of securities issued/allotted under      nil 
 scheme(s) during period (see LR3.5.7G): 
----------------------------------------------------  ---------------------------------------------------------------- 
 Equals: Balance under scheme(s) not yet 
  issued/allotted at end of period                     757,476 
----------------------------------------------------  ---------------------------------------------------------------- 
 Number and class of securities originally admitted    1,779,000 ordinary shares of GBP0.002 each, admitted on 13 July 
 and the date of admission                             2015 
----------------------------------------------------  ---------------------------------------------------------------- 
 Name of contact:                                      Julian Smith 
----------------------------------------------------  ---------------------------------------------------------------- 
 Telephone number of contact:                          [phone] 
----------------------------------------------------  ---------------------------------------------------------------- 
 
 

Enquiries:

 
   Abzena plc 
    John Burt, Chief Executive Officer Julian 
    Smith, Chief Financial Officer                   [phone] 
   Numis (Nominated Adviser and Broker) 
    Clare Terlouw / James Black / Paul Gillam        [phone] 
   N+1 Singer (Joint Broker) 
    Aubrey Powell / Liz Yong                         [phone] 
   Instinctif Partners                               [phone] 
    Melanie Toyne Sewell / Alex Shaw                  [e-mail] 
 

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'Abzena inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'Abzena inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

   --      Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --      Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

-- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

   --      GMP manufacturer of ADC linkers, payloads & combined linker-payloads. 

For more information, please see www.abzena.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRRJMRTMBMMBPR

(END) Dow Jones Newswires

July 03, 2017 13:11 ET (17:11 GMT)